patient receives pioneering lung cancer vaccine in World First
On Jul. 30, 2026, researchers and clinicians from the University of Liverpool and the Clatterbridge Cancer Centre (CCC)…
-
-
Immunotherapy shows promise in treating deadly brain tumours
On Jul. 1, 2026, a study led by a researcher based at King’s College London and McMaster University…
-
USC Stem Cell-led team creates a renewable cell source for cancer immunotherapy and beyond
On Jun. 19, 2026, University of Southern California (USC) scientists report in a paper published in Cell, a…
-
ImmunityBio Achieves Milestone with Large-Scale NK Cell Production and Cryopreservation from Over 60 Healthy and Cancer Donors
On Mar. 13, 2026, ImmunityBio announced the successful completion of manufacturing engineering programs, NK2022 and NK2023, establishing a…
-
BriaCell Reports Sustained Complete Resolution of Lung Metastasis in Bria-OTS(TM) Patient
On Jan. 13, 2026, BriaCell Therapeutics announces the durable and sustained complete resolution of a lung metastasis in…
-
Adaptive Inks deals with Pfizer to support research in rheumatoid arthritis and other immune-related diseases woth $890 Million
On Dec. 15, 2025, Adaptive Biotechnologies announced it has signed two non-exclusive deals with Pfizer to support research…
-
Woman in cancer remission for record 19 years after CAR-T immune treatment
On Feb. 17, 2025, researchers from Texas Children’s Hospital in Houston announced that the four year old girl…
-
iBio Discovers Novel Antibody Targeting Activin E in Collaboration with AstralBio
On Jan. 7, 2025, IBIO an AI-driven innovator of precision antibody immunotherapies, in collaboration with AstralBio announced the…
-
New CRISPR Toolkit to Allow Remote-Controlled Genome Editing
On Dec. 2, 2024, engineers in the University of Southern California (USC) Alfred E. Mann Department of Biomedical…
-
Biotechnology | Diagnostics | Disease | Neurology | Oncology | Therapeutics
new Glioblastoma treatment attacks brain tumors from multiple angles
On Nov. 12, 2024, researchers from the University of Basel and University Hospital Basel announced they had developed…
-
Combination approach showed promise for treating rare, aggressive cancers
On Nov. 12, 2024, a research team led by UCLA Health Jonsson Comprehensive Cancer Center investigators has shown that…
-
largest population-based study to date supported the survival benefits of immunotherapy for people with metastatic non-small cell lung cancer
On Jul. 29, 2024, a team led by Dipesh Uprety, M.D., FACP, of the Barbara Ann Karmanos Cancer…
-
Hutchinson Cancer Center announced $710.5 million gift to support cancer and infectious disease research, ‘skin-on-chip’ technology
On Oct. 12, 2022, the Fred Hutchinson Cancer Center (FHCRC) announced the Bezos family had committed $710.5 million…
-
Landmark Nature Study Provided Long-Sought Mechanistic link between EBV and Multiple Sclerosis
On Jan. 24, 2022, Atara Biotherapeutics, a leader in T-cell immunotherapy, announced that it had leveraged its novel…
-
Oral immunotherapy induced remission of peanut allergy in some young children
On Jan. 20, 2022, a clinical trial funded by the National Institutes of Health (NIH) found that giving…
-
Athenex and Center for Cell and Gene Therapy announced allowance of first U.S. patent around CAR-NKT cell therapy
On Oct. 18, 2021, Athenex and the Center for Cell and Gene Therapy at Baylor College of Medicine,…
-
Biotechnology | Diagnostics | Disease | FDA | Oncology | Radiology | Therapeutics
FDA approved Roche’s Tecentriq as adjuvant treatment for certain people with early non-small cell lung cancer
On Oct. 15, 2021, Roche announced that the U.S. Food and Drug Administration (FDA) had approved Tecentriq (atezolizumab)…
-
Biotechnology | Diagnostics | Disease | FDA | Oncology | Radiology | Therapeutics
FDA approved LUMAKRAS for patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer
On May 28, 2021, Amgen announced that the U.S. Food and Drug Administration (FDA) had approved LUMAKRAS (sotorasib)…
-
Roswell Park, Wilmot Cancer Institute collaborated on first large study of immunotherapy in black cancer patients
On Apr. 20, 2021, a new collaboration between Roswell Park and the Wilmot Cancer Institute was announced that…
-
FDA approved first immunotherapy for initial treatment of gastric cancer
On Apr. 16, 2021, the FDA approved Bristol-Myers Squibb’ s Opdivo (nivolumab), in combination with certain types of…
-
Biotechnology | FDA | Oncology | Therapeutics
FDA approved Bristol Myers Squibb’s and bluebird bio’s Abecma for Relapsed or Refractory Multiple Myeloma
On Mar. 26, 2021, Bristol Myers Squibb and bluebird bio announced that the U.S. Food and Drug Administration…
-
Notch Therapeutics closed $85 million financing to develop pipeline of renewable stem cell-derived cancer immunotherapies
On Feb. 10, 2021, Notch Therapeutics closed $85 Million Series A financing to develop pipeline of renewable stem…
-
BioNTech and InstaDeep announce AI Innovation Lab to develop novel immunotherapies
On Nov. 25, 2020, BioNTech and InstaDeep announced a multi-year strategic collaboration aimed at applying the latest advances…
-
Corvus completed enrollment in phase 1 study of CPI-006 for patients with COVID-19
On Nov. 9, 2020, Corvus Pharmaceuticals announced that it had completed patient enrollment in its Phase 1 study…
-
Fred Hutch completed move-in of Lake Union Steam Plant
On Nov. 9, 2020, after more than two years of reconstruction efforts, scientists from the Fred Hutchinson Cancer…
-
New CAR T-Cell therapy approved and available at Roswell Park for lymphoma patients
On Oct. 13, 2020, Roswell Park Comprehensive Cancer Center announced that it had been approved to administer the…
-
Data from Corvus phase 1 study of CPI-006 continued to support its potential as treatment for COVID-19
On Oct. 5, 2020, Corvus Pharmaceuticals announced that it has initiated a Phase 1 study to investigate a…
-
Corvus Pharmaceuticals provided update on clinical trial of CPI-006 for patients with COVID-19
On Sept. 10, 2020, Corvus Pharmaceuticals announced updated data from its ongoing Phase 1 study investigating the potential…
-
Corvus Pharmaceuticals initiated clinical trial of novel immunotherapy for patients with COVID-19
On Jul. 7, 2020, Corvus Pharmaceuticals announced that it has initiated a Phase 1 study to investigate a…
-
Biotechnology | FDA | Medicine | Oncology | Pharmaceutical | Radiology | Therapeutics
FDA approved Bristol-Myers’ Opdivo’ (nivolumab) for treatment of patients with advanced esophageal squamous cell carcinoma
On Jun. 11, 2020, Bristol-Myers Squibb announced that Opdivo ® (nivolumab) was approved by the U.S. Food and…
